Immunovant (IMVT) News Today $16.90 +0.17 (+1.02%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$16.97 +0.07 (+0.41%) As of 10/3/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMVT Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Platinum Investment Management Ltd. Grows Position in Immunovant, Inc. $IMVTOctober 2 at 6:35 AM | marketbeat.comJP Morgan Maintains Immunovant (IMVT) Overweight RecommendationOctober 1 at 11:58 AM | msn.comImmunovant (NASDAQ:IMVT) Given New $33.00 Price Target at JPMorgan Chase & Co.September 30, 2025 | marketbeat.comWhere is Immunovant (IMVT) Heading According to Analysts?September 30, 2025 | msn.comBanque Pictet & Cie SA Has $2.02 Million Stock Holdings in Immunovant, Inc. $IMVTSeptember 27, 2025 | marketbeat.comAnalysts Set Immunovant, Inc. (NASDAQ:IMVT) PT at $33.60September 23, 2025 | americanbankingnews.comAnalysts Are Bullish on Top Healthcare Stocks: Immunovant (IMVT), Ascentage Pharma Group International Unsponsored ADR (AAPG)September 20, 2025 | theglobeandmail.comImmunovant, Inc. (NASDAQ:IMVT) Given Consensus Rating of "Moderate Buy" by AnalystsSeptember 20, 2025 | marketbeat.comWoodline Partners LP Boosts Stock Position in Immunovant, Inc. $IMVTSeptember 12, 2025 | marketbeat.comImmunovant (IMVT) Highlights New Graves’ Disease Data Can Its Pipeline Deliver Sustainable Innovation?September 11, 2025 | finance.yahoo.comAdage Capital Partners GP L.L.C. Reduces Stake in Immunovant, Inc. $IMVTSeptember 10, 2025 | marketbeat.comCubist Systematic Strategies LLC Increases Holdings in Immunovant, Inc. $IMVTSeptember 10, 2025 | marketbeat.comA Look at Immunovant's Valuation Following New Batoclimab Data Update for Graves' DiseaseSeptember 9, 2025 | finance.yahoo.comTwo Seas Capital LP Purchases 131,158 Shares of Immunovant, Inc. $IMVTSeptember 9, 2025 | marketbeat.comImmunovant, Inc. $IMVT Shares Purchased by Granahan Investment Management LLCSeptember 8, 2025 | marketbeat.comEFG Asset Management North America Corp. Acquires 56,375 Shares of Immunovant, Inc. $IMVTSeptember 7, 2025 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for Immunovant (NASDAQ:IMVT)September 6, 2025 | marketbeat.comCanada Pension Plan Investment Board Grows Stock Holdings in Immunovant, Inc. $IMVTSeptember 6, 2025 | marketbeat.comImmunovant (NASDAQ:IMVT) Stock Price Up 10% - Time to Buy?September 5, 2025 | marketbeat.comADAR1 Capital Management LLC Has $16.56 Million Position in Immunovant, Inc. $IMVTSeptember 4, 2025 | marketbeat.comRedmile Group LLC Cuts Stake in Immunovant, Inc. $IMVTSeptember 4, 2025 | marketbeat.comVestal Point Capital LP Buys 305,000 Shares of Immunovant, Inc. $IMVTSeptember 4, 2025 | marketbeat.comBaker BROS. Advisors LP Boosts Holdings in Immunovant, Inc. $IMVTSeptember 4, 2025 | marketbeat.comInvesco Ltd. Has $945,000 Holdings in Immunovant, Inc. $IMVTSeptember 4, 2025 | marketbeat.comImmunovant: 80% of patients demonstrate response in Graves’ disease trialSeptember 4, 2025 | msn.comRoivant Sciences Ltd. - Immunovant Batoclimab Graves' Disease Proof-Of-Concept Study Remission Data TranscriptSeptember 3, 2025 | seekingalpha.comImmunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease PatientsSeptember 3, 2025 | globenewswire.comOMERS ADMINISTRATION Corp Acquires Shares of 48,300 Immunovant, Inc. $IMVTSeptember 3, 2025 | marketbeat.comImmunovant, Inc. $IMVT Holdings Boosted by Alpine Global Management LLCSeptember 2, 2025 | marketbeat.comRafferty Asset Management LLC Acquires 22,213 Shares of Immunovant, Inc. $IMVTSeptember 2, 2025 | marketbeat.comDAFNA Capital Management LLC Purchases 62,000 Shares of Immunovant, Inc. $IMVTSeptember 1, 2025 | marketbeat.com233,985 Shares in Immunovant, Inc. $IMVT Purchased by Nuveen LLCAugust 30, 2025 | marketbeat.comRoivant Sciences (ROIV) Announces Q1 2025 Business UpdateAugust 29, 2025 | finance.yahoo.comImmunovant Stockholders Approve Key Governance DecisionsAugust 28, 2025 | tipranks.comImmunovant, Inc. $IMVT Shares Purchased by Affinity Asset Advisors LLCAugust 28, 2025 | marketbeat.comJump Financial LLC Raises Stock Holdings in Immunovant, Inc. $IMVTAugust 28, 2025 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Receives Consensus Rating of "Moderate Buy" from AnalystsAugust 28, 2025 | marketbeat.comIMVT Investors Have Opportunity to Join Immunovant, Inc. Fraud Investigation with the Schall Law FirmAugust 27, 2025 | businesswire.comCharles Schwab Investment Management Inc. Grows Position in Immunovant, Inc. $IMVTAugust 26, 2025 | marketbeat.comSwiss National Bank Acquires 30,800 Shares of Immunovant, Inc. $IMVTAugust 25, 2025 | marketbeat.comT. Rowe Price Investment Management Inc. Increases Holdings in Immunovant, Inc. $IMVTAugust 24, 2025 | marketbeat.comVanguard Group Inc. Raises Stock Holdings in Immunovant, Inc. $IMVTAugust 24, 2025 | marketbeat.comAberdeen Group plc Increases Stock Position in Immunovant, Inc. $IMVTAugust 21, 2025 | marketbeat.comDeutsche Bank AG Raises Stake in Immunovant, Inc. (NASDAQ:IMVT)August 18, 2025 | marketbeat.comTejara Capital Ltd Makes New Investment in Immunovant, Inc. (NASDAQ:IMVT)August 17, 2025 | marketbeat.comQ2 Earnings Estimate for Immunovant Issued By HC WainwrightAugust 16, 2025 | marketbeat.comQ2 EPS Estimates for Immunovant Decreased by Leerink PartnrsAugust 16, 2025 | marketbeat.comLifesci Capital Predicts Immunovant Q2 EarningsAugust 16, 2025 | marketbeat.comRoivant Sciences: Vant Model And IMVT-1402 Create A 2025 Catalyst StackAugust 15, 2025 | seekingalpha.comConnor Clark & Lunn Investment Management Ltd. Purchases 128,345 Shares of Immunovant, Inc. (NASDAQ:IMVT)August 14, 2025 | marketbeat.com Get Immunovant News Delivered to You Automatically Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMVT Media Mentions By Week IMVT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMVT News Sentiment▼0.230.53▲Average Medical News Sentiment IMVT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMVT Articles This Week▼56▲IMVT Articles Average Week Get the Latest News and Ratings for IMVT and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Immunovant and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies SLNO News Today VTRS News Today ROIV News Today QGEN News Today ELAN News Today BBIO News Today MRNA News Today VRNA News Today RVMD News Today GRFS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMVT) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated b...Banyan Hill Publishing | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gol...StockEarnings | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunovant With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
